Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal ...
New Phase II/III study will evaluate ivonescimab plus chemotherapy against existing immunotherapy-based treatments, building ...
The IMPACT31 trial will enrol 90 high-risk liver cancer patients across the US and Asia-Pacific to evaluate GNOS-PV02 ...
New CAS Connections integration combines over 150 years of curated scientific knowledge with CAS Newton’s agentic AI ...
NeuroXT Inc., a medical device manufacturer, announced that NEXT-Cue, its AI-based Software as a Medical Device (SaMD) ...
Medical device makers went digital to stay audit-ready. Yet their device history records are still being stitched together by ...
ESTEVE CDMO, Esteve Healthcare contract development and manufacturing organization, is strengthening its presence in Asia ...
Operating profit reaches KRW 640 billion as Plant 5 ramp-up and US operations strengthen performance, prompting the CDMO ...
Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone payment from Servier. The multi-targets oncology collaboration of both parties, ...
Metabolon, Inc., the global leader in metabolomics solutions advancing life sciences research, diagnostics, therapeutics, and precision medicine, announced Splash & Ripple, a new bioinformatics ...
Phase I study will evaluate three novel multi-stage VLP-based vaccine candidates targeting Plasmodium falciparum and Plasmodium vivax, aiming to advance protection against malaria infection, disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results